Financial Performance - In the first half of 2023, the company's operating revenue was ¥112,225,810.15, a decrease of 27.01% compared to ¥153,751,776.79 in the same period last year[27]. - The gross profit margin for the first half of 2023 was 18.13%, down from 28.18% in the previous year[27]. - The net profit attributable to shareholders of the listed company was ¥10,245,890.81, representing a decline of 60.98% from ¥26,257,163.71 in the same period last year[27]. - The net profit after deducting non-recurring gains and losses was ¥8,889,919.72, down 64.40% from ¥24,973,970.37 year-on-year[27]. - The weighted average return on net assets based on net profit attributable to shareholders was 2.61%, a decrease from 16.72% in the previous year[27]. - Operating cash flow decreased by 26.90% to ¥32,148,479.36 from ¥43,976,719.02 year-over-year[29]. - Net profit decreased by 60.98% compared to the same period last year[30]. - The company achieved a net non-recurring profit of ¥1,355,971.09 after tax[32]. - The company reported a 216.13% increase in revenue from rutin and a 178.89% increase in revenue from berberine, contributing to overall profit growth[41]. - The company’s external sales revenue grew by 6.39% year-on-year, while internal sales revenue fell by 35.86%[66]. Assets and Liabilities - Total assets decreased by 3.23% to ¥426,252,902.73 from ¥440,473,318.89 year-over-year[28]. - Total liabilities decreased by 18.96% to ¥40,703,541.34 from ¥50,225,567.49 year-over-year[28]. - The company's cash and cash equivalents decreased by 38.52% to 118,479,830.62 CNY, primarily due to cash payments for project construction and bank loan repayments[54]. - Accounts receivable decreased by 39.67% to 36,407,318.76 CNY, attributed to improved customer credit management strategies[54]. - The company's construction in progress increased by 308.25% to 51,234,431.25 CNY, reflecting significant investment in project upgrades and expansions[54]. - The total current assets decreased from CNY 378,983,354.45 as of December 31, 2022, to CNY 320,567,537.36 as of June 30, 2023, representing a decline of approximately 15.4%[120]. - The total non-current assets increased from CNY 61,489,964.44 as of December 31, 2022, to CNY 105,685,365.37 as of June 30, 2023, indicating an increase of approximately 71.8%[122]. - The total liabilities decreased from CNY 50,225,567.49 as of December 31, 2022, to CNY 40,703,541.34 as of June 30, 2023, reflecting a reduction of about 19.0%[123]. Investments and Fundraising - The company is actively advancing its fundraising projects, with the "Chengdu Okay Pharmaceutical Co., Ltd. Technical Transformation and Expansion Project (Phase I)" progressing smoothly according to plan[7]. - The company has invested an additional ¥35 million in fundraising projects to improve product quality and production efficiency[36]. - The company raised a total of RMB 231,500,556.80 from the public offering of shares, with a net amount of RMB 212,317,682.73 after deducting issuance costs[105]. - As of June 30, 2023, the cumulative investment in fundraising projects amounted to RMB 135,762,100, with RMB 101,566,700 used during the reporting period[106]. - The balance of the fundraising account as of June 30, 2023, was RMB 79,961,000[106]. Research and Development - The company has obtained two invention patents, bringing the total number of patents to 36 as of the report date[5]. - The company has obtained two invention patents related to the preparation processes of flavonoids, enhancing its competitive edge in cost reduction and innovation[37]. - R&D expenses increased by 13.37% due to heightened investment in innovation, while management, financial, and sales expenses were reduced by 17.55%, 183.55%, and 5.79% respectively[44]. - The company is focusing on research and development of new products and improving production processes to enhance competitiveness[84]. Market Expansion and Strategy - The company established a foreign holding subsidiary, OKAYPHARM USA INC., in Los Angeles to expand into the health product market[8]. - The company plans to expand its product applications in domestic markets, including functional food ingredients and cosmetics, while also developing a health product brand in the U.S. using quercetin[43]. - The company is investing in an automated workshop and digital factory to enhance production efficiency and reduce costs for its products[42]. - The company is actively developing domestic raw materials and functional food markets to mitigate risks from international trade environments[80]. - The company is focused on expanding its market presence both domestically and internationally to achieve a dual-market strategy[80]. Compliance and Certifications - The company has passed multiple quality certifications including EuGMP, FSSC22000, HACCP22000, ISO9001, HALAL, and KOSHER, which are crucial for maintaining market access[80]. - The company has obtained the Pollution Discharge Permit from the Chengdu Ecological Environment Bureau, valid from December 22, 2020, to December 21, 2025[78]. - The company has established an EHS management system to oversee environmental protection and pollution control during production[78]. Shareholder Information - The total number of ordinary shares at the end of the period is 75,631,404, with 25% being unrestricted shares after the conversion of 3,202,320 restricted shares[99][100]. - Major shareholders include Zhao Zhuojun with 31,178,881 shares (41.22%) and Wu Li with 20,748,000 shares (27.43%) at the end of the reporting period[103]. - The total shares held by directors and supervisors amount to 53,370,830, which is 70.55% of the total shares[113]. - The company has not issued any preferred shares or convertible bonds during the reporting period[108]. Financial Management - The company has provided guarantees totaling ¥10,000,000 for loans at both Agricultural Bank of China and China Merchants Bank, with a guarantee period from February 2023 to February 2025[91]. - The company has also guaranteed ¥5,000,000 for a loan at Industrial and Commercial Bank of China, with a guarantee period from June 2023 to June 2024[91]. - The company has completed the repayment of all mortgage loans from Bank of China by June 30, 2023, although the asset release procedures are still pending[96]. Operational Changes - The company has established a comprehensive employee welfare system to ensure fair and healthy working conditions[77]. - The company appointed a new supervisor, Li Hua, due to the resignation of Wei Liuli, ensuring compliance with the legal minimum number of supervisory board members[115]. - The number of total employees increased from 208 at the beginning of the period to 210 at the end of the period, with a net addition of 2 employees[117]. - The number of technical personnel increased from 43 to 46, showing a growth of approximately 7.0%[117].
欧康医药(833230) - 2023 Q2 - 季度财报